22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
AB Science Corporate Presentation
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
10/10/2019 – AB Science provides update on masitinib programs timelines
30/09/2019 – AB Science reports its revenues for the first half of 2019